Constructing food for shareholder value by Kneen, Brewster
This is one way to frame the discussion, but we must recognize that the
title itself — food industry — is a cultural expression. It is a way of seeing
the world. It also implies a monoculture: there is one correct way to view the
world, including food and agriculture. This is the way the wealthy industrial-
ized societies of the North view the world out of their historically and culturally
distinct experience. But what about other perspectives and experiences? A
woman’s perspective, or that of a laid off worker? Or the perspective of a lesser
developed country’s subsistence farmer? Or an aboriginal in Costa Rica, or in
the southwest or north of this continent?
Are we even aware of the biases and assumptions that we take on when we
use the cultural expression “food industry” and do we, or are we willing, to
take account of how others might view these issues?
I am not castigating the NABC, because when I raise these alternatives, I
must say that the NABC looks like the most thoughtful and sincere discussion
on biotechnology going. Look, for comparison, at the hype surrounding the
1996 “Agbiotech International Conference” being held in Saskatoon. “New
Technologies! New Marketing Partners! New Opportunities!” is the conference
slogan. Complete with exclamation marks. In keeping with their slogan, I can
find no indication in their program that there will be any critical discussion of
anything. (Not that this surprises me, given who has organized the event.)
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The Food Industry Workshop: “Evaluate the pathways to
be taken by new agricultural biotechnology food products;
issues of communication, regulation, and concern over
something so ‘personal’ as food; and ways in which the
production of new food crops might impact the structure
of the agricultural industry and the food industry itself.”
Or look at the program for Bio ’96 in Philadelphia. As far as I can see from
the program, there is one workshop, out of about 80, that deals with ethics,
titled “Characterizing & Addressing Ethical Issues.” The information package
states “The Bioethics Committee and industry representatives will discuss case
studies where research and product development yield ethical implications, and
will participate in analysis of ethical implications of case studies.”
The language boggles my mind: what is meant by “yield ethical implications”?
At first I thought there had been a mistake when I saw that I was down to
speak in the Economic and Structural Issues session, rather than yesterday’s
session on Social Issues, Regulations and Ethics. But as I pondered it, I realized
that this is indeed the right slot for me. When I studied theology, ethics was my
major interest. The subject was referred to as Christian ethics or social ethics,
and the focus was largely political and social, not individual and personal. Since
then, I have found myself increasingly focused on economics and its institu-
tions and structures — as well as the values and assumptions on which they are
based. Meanwhile, it seems to me that ‘ethics’ has been increasingly defined in
individualistic terms as issues of personal choice. The rising field of medical
ethics and bioethics is a good illustration of this, where individual choice reigns
supreme and social good does not seem to be even a recognizable category,
much less an ethical framework.
A good example of the application of this individualized ethics is the V-Chip,
described by New Scientist magazine as a way “to banish TV sex and violence
from American homes.” This bit of technology seems to be based on the
assumption that there is no way, or desire, to get rid of TV sex and violence,
along with an acknowledgment of negative effects on children. An obvious
social problem of rather substantial ethical significance is reduced to a matter
of individual parental option.
And while it may strike you as stretching the point, it seems to me that the
labeling of genetically engineered foods is being approached in much the same
way. There appear to be no questions raised either about the production of
violence on TV or about the production of genetically engineered food. In the
case of food, the biotechnology industry promotes the position that it would
be absurd, unworkable, and costly to label genetically engineered food. In a
1993 interview, an FDA spokesperson said: “It would not be merely a matter of
putting a sticker on a tomato or a banana. Producers would have to segregate
the genetically engineered foods from other varieties. Does the label have to
follow the food processing chain? It would increase the cost of these foods to
consumers and would disrupt our complex food distribution system.”1
1 James Maryanski, biotechnology coordinator, Center for Food Safety and Applied Nutrition, FDA,
in a 1993 interview by FDA consumer writer Mary Alice Sudduth.
Monsanto’s 1995 kit for the American Dietetic Association2 takes the same
line: “Some consumers believe that foods derived from new plant varieties
[notice the slick linguistic trick of referring to “new plant varieties”] should be
labeled as such. These individuals [only “individuals,” of course] base their
position on the consumer’s ‘right to know’ the food’s method of production.
Practical considerations make such a position difficult to implement . . . and
would result in increased costs to consumers with no benefits.” Except, of
course, their ability to reject Monsanto’s biotechnological products.
But if there is a problem of informing the public about what they are
expected to purchase and eat, then maybe the production of these foods in
the first place is the real problem, and not labeling at all.
Since this session is on the subject of economic and structural issues, I must
ask why it is that our culture is so loath to examine the structures of business.
For myself, I find it necessary to focus on structures and institutions in order to
properly frame the ethical and social issues, and I seldom use the language I
was once trained to use. In fact, I was a little appalled when I pulled some old
textbooks off my shelf and looked at them from my current perspective. They
were terribly inadequate in the way they framed the questions and in their
cultural bias — typical, I am afraid, of the chauvinism and imperialism of
American culture at the time. But is it any different today?
The processes and products of agricultural biotechnology, as well as their
human counterparts, are expressions of a particular historic culture: the culture
of Enlightenment, Industrial Revolution and Reductionism Science. Biotechnol-
ogy is an artifact of this culture. It is no more a universal outcome of evolution
than our notion of science itself.
In fact, we might describe biotechnology as an apocalyptic remnant of the
19th and 20th century idea of Progress and Development — sustainable or not.
Just recall the language you see in virtually every piece of literature on biotech-
nology: “improved” seeds, “superior” genes, “best” traits, and so on. Mean-
while, fewer and fewer people believe in the myth of progress — and those who
still do are generally of the white northern business class — a rather small elite
of the global population whose own children appear to be rejecting the idea.
Stripped of its emotive language, biotechnology would look like Swiss
cheese — or the brain of a cow suffering from BSE!
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2 “Plant Biotechnology — Harvesting Solutions for Tomorrow’s World”, produced by Monsanto
Company in cooperation with The American Dietetic Association, 1995.
On the basis of its belief in a deterministic understanding of evolutionary
progress, it is not surprising that our culture has taught us that there is only
one valid epistemology, only one way to know about life and the world. We
might well apply the term ‘monoculture’ both to the knowledge system of our
rationalist, industrial culture, and to its practices, for example agriculture.
Our notion of science and technology is, in fact, based on an epistemological
monoculture. One might well add that sexism, racism, and nationalism are also
expressions of monoculture. As in a field of hybrid corn, variation and differen-
tiation are not welcome! They interfere both with the images we have come to
accept as normative and with the production process. The model is still the
production line. (You should see the difference in my garden and my daughter’s
— I have a hard time not planting in tidy rows, while hers is helter-skelter —
herbs, flowers, and vegetables in glorious confusion.)
Lest you think I am being extreme, let me remind you that not very long
ago the term “junk DNA” was used to describe what could not be explained:
because it could not be explained, it was junk. Prions did not exist very long
ago either, much less mutant prions that seem to cross species barriers on their
own. And an article on the genetic blueprinting of yeast in the April 27, 1996
issue of New Scientist made the interesting comment that, “Sequencing the yeast
genome has revealed a vast terra incognita. Biologists have no clue as to the
function of 40 percent of the genes they have identified. Half of these enigmatic
genes have DNA sequences similar to other, equally puzzling genes in fruit flies,
mice, or other organisms, but half have never been seen before. Researchers
have dubbed these genes ‘orphans’ because no one knows which gene families
they belong to.”
I suppose the common response is that we will soon fill in those blanks and
complete our knowledge. But will this be the case, or only the case as we wish
it to be? Unfortunately, we are all too likely to simply ignore (or eliminate or
“disappear”) what does not fit, or, for that matter, other ways of knowing.
I do not say this with malice. I, like most of you, grew up in an era and a
culture of imperialism — only we called it “development”. In this culture it
has been assumed that everyone wants to, and could, become like us. And, of
course, it has been assumed that we know how to make this happen. Agri-
cultural biotechnology, as a reincarnation of the Green Revolution, and based
on the same neo-Malthusian assumptions, is simply the latest artifact to be
devised in pursuit of this goal. Monoculture is a perfectly reasonable phenome-
non in this context. There is one goal, and one way to achieve this goal. Cer-
tainly the propaganda of industrial biotechnology expresses this monoculture.
But I have been taught by others, as well as by my own experience, which I
refuse to invalidate, that there are always more ways than one to know anything
and to do anything. It all depends on perspective, experience, culture.
Now we are faced with a profound contradiction in modern industrial
biotechnology: the claims made for it are that it will enhance life, improve
nutrition, increase biodiversity, and save the environment. Yet it seeks to
achieve this through the violent manipulation of the very foundations of life.
If we look at the medical field, we see the application of biotechnology in
the form of esoteric and heroic measures to defy death, almost exclusively on
an individual basis. It is not vaccines for malaria or treatments for pneumonia
or cholera that get the research — it’s the transgenic animal organs for xeno-
transplantation.
The director of the World Health Organization recently commented that
“The optimism of a relatively few years ago that these [infectious] diseases
could be brought under control has led to a fatal complacency.” The report that
he introduced points out that diseases known for centuries are now popping up
in incurable strains, many of them increasingly resistant to drugs as a result of
“the uncontrolled and inappropriate use of antibiotics.” Making matters worse,
the report points out, are modern methods of food production, such as the
use of antibiotics in meat production to promote growth, but not in sufficient
amounts to kill microbes, with the result that drug-resistant bacteria are then
passed through the food chain to the consumer. “In the contest for supremacy”,
reports the World Health Organization, “the microbes are sprinting ahead.”3
The advocates of biotechnology are quick to claim that what they are doing
is simply more of what we have been doing for millennia — making bread
and wine and cheese. In a sense they are correct. Biotechnology is just another
expression of the drive to control not only the world around us (nature, or
Creation), but also other people. It is fully in keeping with the attitude of
Francis Bacon who, more than 300 years ago, as Sandra Harding points out
so lucidly, used the sexual imagery of rape and torture to describe the proper
scientific attitude toward nature.4
Technology, or technique, is a culturally embedded approach to acting on the
world. It is a set of tools, particular tools that express cultural attitudes and
values, such as speed, or taking things apart to see how they work. In the case
of western industrial society, it is also a technology of domination and control,
over nature, people, and life itself. Biotechnology is specifically the application
of technology to life forms.
If we look candidly at the practice of biotechnology, we see violent interven-
tion in the structures of life in order to reshape it according to our goals and
purposes. In this respect, it can be said that biotechnology is engaged in a form
of structural adjustment, but directed by Ciba-Geigy and Monsanto rather than
by the World Bank and International Monetary Fund (IMF).
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3 Toronto Globe & Mail, 5/20/96
4 Sandra Harding, The Science Question in Feminism, Cornell University Press, 1986, p.116.
Applied to biology, however, structural adjustment is social engineering,
and this should remind us of eugenics, that is, the deliberate selection of
“superior” genes, organisms, people. What else can the constant talk about
“improved” seeds and crops mean? Structural adjustment, whether in the lab
of Plant Genetics System (PGS) or the board room of the IMF, is about selecting
preferred structural characteristics and effectively disposing of those not con-
sidered desirable.
The purpose of structural adjustment is, after all, control. And in a market
economy society this control is translated into profit and the accumulation
of wealth.
In biotechnology and genetic engineering, then, we have simply taken what
may be the final step in a logical process. We are now engaged in the redesign
of life itself, with wealth and eternal life as the goals. (We might also describe
this as an expression of the fear of death.5) We cannot, however, honestly say
that we are trying “to enhance life” in general. It is only those with the money
to buy hopes of immortality that are of interest to the market.
Look at current developments in genetic testing for cancer. While many
social, ethical, and medical questions remain unanswered, including questions
about the efficacy and interpretation of testing itself, companies are gearing up
for large-scale testing for BRCA-1 and the more recently discovered BRCA-2,
genes that “cause” or predispose to cancer. “Profits are expected to be huge.
The cost of Myriad’s new test for BRCA-1 is going to be near $1000 a patient,
and this doesn’t include the cost of the doctor’s examination and counseling
after the results come in,” according to an executive at Myriad Genetics. Myriad
is itself gearing up to test 100,000 women per year.6
Speed kills. This has been a popular slogan to reduce automobile accidents.
As in the case of the V-chip or the labeling of genetically engineered food, the
slogan blames the victim, as it were, rather than putting the blame where it
belongs in the first place, on the automobile manufacturers who build auto-
mobiles to go fast and sell them on the basis of performance, performance
defined as acceleration and speed, or on the investors in the production of
violence for TV.
Isn’t it exactly the same with biotechnology? One of the industry’s favorite
justifications for biotechnology is the speed with which changes can be made
and results achieved — on the assumption, of course, that this is inherently
good. Speed is, after all, what comes with progress: faster aircraft, faster cars,
5 “Having directed so many life trends in North America for the past couple of decades, baby boomers
are looking to dictate new terms for death, including its elimination. With their late first marriages,
late parenthood, second careers, fitness fixations and pharmacological inroads on aging, many of
them — and the social institutions that cater to them — seek to defy and deny the outrage of finite
existence.” (Toronto Globe & Mail, 5/18/96).
6 Toronto Globe & Mail, 7/5/96.
faster trains, faster communications of all sorts — and I just love e-mail! (Let’s
just ignore, for now, the contradiction between speeding fruit by jet from Chile
to Canada while it has also been designed for longer shelf-life.)
Currently the biotech industry is making a great push to have its notion
of the benefit of speed applied to the regulatory system. Quick approval has
somehow become a desirable goal, a ‘good thing’. ‘You can’t stand in the way
of progress’, we are told.
The Canadian Government’s proposed revisions to the Environmental Pro-
tection Act are a good illustration of this. In its position paper the government
stresses that it is “the new paradigm of global competitiveness” and “the ability
to innovate and respond to new technologies [that] determines corporate suc-
cess,” and says that it “wants to ensure that we have a regulatory regime in
place which . . . places Canadians at a competitive advantage.”7 What little it
says about social or ecological health is strictly an addendum to
competitiveness.
I do not think that a cynical response is out of order. If the regulation of bio-
technology is subject to such mindless criteria, we will indeed be able to say
that ‘speed kills’ — but it will be too late. The point of a regulatory process is
not speeding new products to market in the name of global competitiveness. It
is sanity and health — not the health of the market or the corporation, but the
health of the society and all life.
Unfortunately, industry seems to see itself as above and beyond society, and
its corporate health as achievable without public benefit or control. As a result,
we see industry engaged in blackmail, in Germany and other jurisdictions
around the world, saying that if the regulatory process is not liberalized and
speeded up, it will take its business elsewhere. So now we are in a game of
competing globally to see who can get away with the lowest standards. It is
genuinely frightening!
The second characteristic of biotechnology is supposedly the precision of its
processes. The industry makes much of this precision, although many prac-
titioners deny it exists. Even if the precision is real, we must still question its
value; after all, it is precisely the lack of precision that makes it possible for
organisms to evolve and survive.
What is more interesting, however, in terms of the structural issues we
should be addressing, is the fact that both speed and precision are character-
istics of process, not product. So we are faced with this contradiction: the
industry claims it is the process which makes the products of genetic engineer-
ing superior to traditional plant breeding, then turns around and says that as
far as regulation and labeling are concerned, it is only the product that counts.
Kneen
7  CEPA Review: The Government Response, Ottawa, 1995, p.5 & p.51.
Let’s look more closely at this process-product issue, because it is present
at every level, from Codex Alimentarius to the City of Toronto’s Food Policy
Council.
I think the biotechnology industry is right to resist the labeling of foods as
products of biotechnology. They know the public concern, and they know that
the public does not make the process/product distinction that the industry
would like them to. Why should the public make this distinction? In Ontario,
for example, kosher dairy products have been on the market for quite a while,
labeled as such. And halal is also recognized. Yet when a very substantial group
of organic diary farmers wanted to market certified organic dairy products, the
Ontario Milk Marketing Board fought them all the way, saying they could not
make an exception to the rule of monoculture. The OMMB lost, and organic
milk is now on the Ontario market and doing very well. The underlying
concern here was well expressed by the exasperated comment of a western beef
rancher: “What am I, inorganic?” It is assumed that the organic label indicates a
superior product. This is acceptable when the group for whom the product is
superior is small or marginal (Jews, Muslims, people allergic to peanuts), but it
becomes terrifying when the assumed superiority has a more general appeal as a
more wholesome, less high-tech or manipulated food.
The recent meeting of the labeling working group of Codex Alimentarius in
Ottawa had to wrestle with this process/product issue: on its agenda was the
labeling of halal, kosher, organic, and biotechnology foods. All are process
issues, but not much headway was made on the biotech issue because there was
no agreement to proceed on the basis of the U.S. position that how a food is
created, grown or processed is irrelevant — at least in the case of biotech foods.
In the FDA interview cited earlier, in response to the question, “What values
will these genetically engineered plants have — more nutrients, better taste?”
the FDA spokesperson had an honest response: “Right now, it’s more a matter
of giving fruits and vegetables better shelf-life and shipping properties.” In food
production, genetic engineering is being applied primarily to the industrial
commodity crops: tomatoes, corn, oilseeds, soybeans, potatoes and cotton.
These are not crops that are in short supply or that need, as the industry calls
it, improving. And what has been done to them is to make them more amenable
to monoculture industrial production — regardless of what the companies
might say about nutrition and the environment. These crops are being adjusted
structurally in order to provide greater sales and profits for a very limited
number of very large transnational corporations — corporations that are getting
fewer in number and larger every day. (The merger of Ciba-Geigy and Sandoz
into Novartis is just the latest and largest. Monsanto, meanwhile, is busy with
another kind of expansion, having taken control of Gargiulo and Calgene in
recent months.)
Even the World Bank is getting concerned. An agricultural specialist with
the bank recently warned a Saskatoon audience that biotechnology might start
avoiding research of public value, but little private profit. “Who is going to
make the public good investments in fundamental research to agriculture?”
Alex McAlla asked.8
At the same time, there is another sort of structural adjustment going on.
One begins to realize that ‘jobless recovery’ and ‘downsizing’ and a whole lot
of other euphemisms are really telling us that the corporation is no longer
interested in production. It is not sales that count, as a look at the way Forbes’
magazine rates companies reveals. What counts is equity and return on equity,
dividends, and increases in share value. These are all expressions of what is
now being heralded as “shareholder value”. Another expression of this is the
preoccupation of business with the financial markets, that is, those markets
where the trading is not done in real commodities, things that people can
actually eat or use to keep warm, but in invisible or imaginary commodities,
such as derivatives that are based on the movement of stock indices or currency
exchange rates.
If we are honest about it, we must conclude that, as presently practiced,
biotechnology is going to offer nothing to the subsistence farmer anywhere —
except perhaps lower prices for what little surplus he or she may try to sell.
What it promises is greater ‘shareholder value’ for wealthy northern investors,
much of this to be derived from the value-added activities of everyone from the
biotechnologist to the further-processor. But this shareholder value is simply an
extraction or transfer of wealth that has nothing to do with social benefit,
personal well-being, or even nutrition.9
In the case of food, value-added is used to describe anything that might
provide an opportunity to increase the selling price of a product, from simply
washing potatoes instead of selling them covered with mud to turning them
into pre-cooked frozen french fries, or what’s worse, reprocessed, cooked, and
canned “Pringles” (now P&G’s biggest export product). And in practice, value-
added largely means nutrition-subtracted.
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8 Working Paper:23/5/96 .
9 “Imperial Oil aims to boost shareholder value” was a recent newspaper headline: “Imperial Oil is
considering a number of moves to boost shareholder value, including buying back a large chunk of
stock or paying a special dividend... Investors believe the company’s managers will take bold steps
to enhance the value of its stock. A large buyout would have that effect, as it would dramatically
increase demand for the stock. At March 31, Imperial, Canada’s largest integrated oil company, had
$2 billion in cash and marketable securities, with $1.8 billion in debt. In 1995 it earned $514 million
on revenue of $9.4 billion.” (Globe and Mail: 5/14/96) .
When I butchered the lambs we had raised, I did not consider that I was
adding value. I was, first of all, taking a life. Second, I was putting that animal
in a more attractive and convenient form for human consumption. I was not
adding value to the meat of that lamb as a delicious and nutritious food.
Another example from my experience as a sheep farmer. We found it
necessary, for our survival, to organize a cooperative. It was a non-share capital,
farmer owned and operated co-op that took charge of marketing lambs for the
sheep farmers of Nova Scotia on a voluntary basis. That is, there was no legal
compulsion or authority in what we were doing. What we did, in fact, was gain
control of lamb marketing — from the farmer through delivery to the super-
markets. We had to concentrate power and control in order to gain a reasonable
return on our labor. Not to make a profit, not to make a return on our capital,
and not to increase shareholder value for the co-op, but to hopefully make a
living wage.
The application of biotechnology to food is often described as ‘adding value’.
I can see the added cost aspect of it, particularly given the new emphasis on
intellectual property rights, though the speed of new product development is
outrunning the patent process. However, I have yet to see any indication of the
added nutritional value that the industry uses as a selling point, particularly
with gullible health professionals and their organizations, such as the American
Dietetics Association (ADA) and Canadian Dietetics Association (CDA).
So when we look at agriculture, and at that application of biotechnology to
agriculture, we readily see that it is not about feeding the hungry of the world,
or even the growing population of the world, in fact. Nor is it even, really,
about feeding the growing appetites of the growing global middle class. What
it is about is making more money for corporations out of what is already being
produced. We are, in fact, in the midst of a massive structural adjustment for
the simple purpose of increasing shareholder value.
We are fond of referring to this new economy as an information economy,
and noting that DNA is merely a form of information, which can be manipu-
lated for profit just like other forms of information. Considering the global
economic structural adjustment I have been describing, I think it may be more
accurate to describe this as a post-production economy. I leave you with that
thought.
